CX Institutional’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.37M | Sell |
58,297
-76,191
| -57% | -$10M | 0.21% | 118 |
|
|
2026
Q1 | $18.7M | Buy |
134,488
+54,802
| +69% | +$7.67M | 0.57% | 37 |
|
|
2025
Q4 | $9.78M | Buy |
79,686
+5,774
| +8% | +$702K | 0.29% | 81 |
|
|
2025
Q3 | $8.2M | Buy |
73,912
+3,419
| +5% | +$389K | 0.25% | 94 |
|
|
2025
Q2 | $7.82M | Buy |
70,493
+1,846
| +3% | +$196K | 0.27% | 73 |
|
|
2025
Q1 | $7.69M | Buy |
68,647
+4,360
| +7% | +$450K | 0.29% | 80 |
|
|
2024
Q4 | $5.94M | Buy |
64,287
+3,300
| +5% | +$297K | 0.24% | 98 |
|
|
2024
Q3 | $5.11M | Buy |
60,987
+15,545
| +34% | +$1.19M | 0.23% | 121 |
|
|
2024
Q2 | $3.12M | Sell |
45,442
-2,446
| -5% | -$163K | 0.15% | 158 |
|
|
2024
Q1 | $3.51M | Buy |
47,888
+1,024
| +2% | +$78.7K | 0.17% | 146 |
|
|
2023
Q4 | $3.8M | Buy |
46,864
+7,680
| +20% | +$598K | 0.2% | 132 |
|
|
2023
Q3 | $2.94M | Sell |
39,184
-19,811
| -34% | -$1.52M | 0.16% | 167 |
|
|
2023
Q2 | $4.55M | Buy |
58,995
+2,411
| +4% | +$192K | 0.24% | 127 |
|
|
2023
Q1 | $4.71M | Buy |
56,584
+48,011
| +560% | +$3.98M | 0.25% | 111 |
|
|
2022
Q4 | $736K | Buy |
8,573
+889
| +12% | +$70.4K | 0.04% | 317 |
|
|
2022
Q3 | $474K | Sell |
7,684
-28,164
| -79% | -$1.78M | 0.03% | 341 |
|
|
2022
Q2 | $2.22M | Buy |
35,848
+3,207
| +10% | +$199K | 0.17% | 156 |
|
|
2022
Q1 | $1.94M | Sell |
32,641
-4,566
| -12% | -$292K | 0.16% | 157 |
|
|
2021
Q4 | $2.7M | Sell |
37,207
-14,837
| -29% | -$1.02M | 0.21% | 138 |
|
|
2021
Q3 | $3.63M | Buy |
52,044
+700
| +1% | +$49.2K | 0.3% | 92 |
|
|
2021
Q2 | $3.54M | Buy |
51,344
+3,254
| +7% | +$217K | 0.29% | 95 |
|
|
2021
Q1 | $3.11M | Buy |
48,090
+46,333
| +2,637% | +$2.99M | 0.28% | 95 |
|
|
2020
Q4 | $102K | Buy |
1,757
+747
| +74% | +$45.1K | 0.01% | 358 |
|
|
2020
Q3 | $64K | Buy |
1,010
+140
| +16% | +$9.71K | 0.01% | 358 |
|
|
2020
Q2 | $67K | Buy |
870
+57
| +7% | +$4.37K | 0.01% | 319 |
|
|
2020
Q1 | $61K | Buy |
813
+428
| +111% | +$29.6K | 0.01% | 301 |
|
|
2019
Q4 | $25K | Sell |
385
-477
| -55% | -$31.1K | ﹤0.01% | 326 |
|
|
2019
Q3 | $55K | Sell |
862
-258
| -23% | -$16.9K | 0.01% | 289 |
|
|
2019
Q2 | $76K | Sell |
1,120
-1,310
| -54% | -$86.2K | 0.01% | 293 |
|
|
2019
Q1 | $158K | Buy |
2,430
+2,373
| +4,163% | +$158K | 0.03% | 230 |
|
|
2018
Q4 | $4K | Buy |
+57
| New | +$3.98K | ﹤0.01% | 406 |
|
Other funds holding GILD
CX Institutional's GILD Position: Q2 2026 in Review
CX Institutional reduced its Gilead Sciences (GILD) stake by 57% in Q2 2026, selling an estimated $10M and leaving 58,297 shares worth $7.37M. The position accounts for 0.21% of the portfolio, ranked #118.
CX Institutional first reported a position in GILD in Q4 2018 and has held it in 31 quarters since. The position peaked at $18.7M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- CX Institutional held 58,297 shares of Gilead Sciences worth $7.37M as of Q2 2026.
- CX Institutional sold 76,191 Gilead Sciences shares in Q2 2026, an estimated $10M.
- Gilead Sciences made up 0.21% of CX Institutional's portfolio in Q2 2026, its #118 holding.
- CX Institutional first reported a position in Gilead Sciences in Q4 2018 and has held it in 31 quarters since.
- CX Institutional's Gilead Sciences position peaked at $18.7M in Q1 2026.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.